← Back to Clinical Trials
Recruiting NCT07160868

NCT07160868 Obstructive Sleep Apnoea and Difficult Asthma (OSADA)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07160868
Status Recruiting
Phase
Sponsor St. James's Hospital, Ireland
Condition Asthma (Diagnosis)
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2025-09
Primary Completion 2025-12

Trial Parameters

Condition Asthma (Diagnosis)
Sponsor St. James's Hospital, Ireland
Study Type INTERVENTIONAL
Phase N/A
Enrollment 80
Sex ALL
Min Age 18 Years
Max Age 90 Years
Start Date 2025-09
Completion 2025-12
Interventions
Continuous positive airway pressure (CPAP)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The OSADA (Obstructive Sleep Apnoea in Difficult Asthma) trial is an open-label, randomized control trial investigating the impact of diagnosing and treating obstructive sleep apnoea (OSA) on a asthma control in patients with difficult-to-control asthma. Participants will undergo home-based sleep studies to assess for OSA and are then allocated to one of three arms: 1) Patients with OSA treated with CPAP (intervention group), 2) Patients with OSA not treated for OSA (control group) and 3) Patients without OSA (reference group). The primary objective is to evaluate whether treating OSA improves asthma control, symptom burden, and quality of life compared to untreated OSA and to patients without OSA. Secondary outcomes include exacerbation rates, sleep quality, and healthcare utilization. This trial aims to clarify the contribution of OSA to poor asthma control and the potential benefits of integrated sleep and respiratory care in this complex population.

Eligibility Criteria

Inclusion Criteria: * Patients must have a clinical diagnosis of asthma with supportive objective diagnostics including but not limited to, variable airflow obstruction, bronchial-hyper responsiveness and demonstrable eosinophilic inflammation via fractional exhaled nitric oxide or peripheral eosinophilia * Patients receiving step 4 or step 5 of 'The Global Initiative for Asthma' (GINA) treatment guidelines will be selected * Between the ages of 18 to 90 years of age Exclusion Criteria: * Patients with previous sleep study investigations * Excessive daytime sleepiness; ESS \>17 * Previous diagnosis of a sleep disorder * Resting hypoxaemia or need for long-term oxygen therapy * Inability to provide informed consent

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology